ECSP23086661A - Forma cristalina del compuesto derivado tricíclico, método para preparar la misma y composición farmacéutica que comprende la misma - Google Patents

Forma cristalina del compuesto derivado tricíclico, método para preparar la misma y composición farmacéutica que comprende la misma

Info

Publication number
ECSP23086661A
ECSP23086661A ECSENADI202386661A ECDI202386661A ECSP23086661A EC SP23086661 A ECSP23086661 A EC SP23086661A EC SENADI202386661 A ECSENADI202386661 A EC SENADI202386661A EC DI202386661 A ECDI202386661 A EC DI202386661A EC SP23086661 A ECSP23086661 A EC SP23086661A
Authority
EC
Ecuador
Prior art keywords
same
crystalline form
tricyclic
preparing
pharmaceutical composition
Prior art date
Application number
ECSENADI202386661A
Other languages
English (en)
Inventor
Seong Hyeon Jeon
Jung Gi An
John Kim
Original Assignee
Onconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconic Therapeutics Inc filed Critical Onconic Therapeutics Inc
Publication of ECSP23086661A publication Critical patent/ECSP23086661A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a: una forma cristalina de una sal de ácido cítrico de un compuesto derivado tricíclico representado por la fórmula química 1, un método para preparar la forma cristalina de la sal de ácido cítrico; y una forma cristalina del compuesto derivado tricíclico representado por la fórmula química 1, en donde la forma cristalina del compuesto derivado tricíclico se usa de manera eficaz en la preparación de la forma cristalina de la sal de ácido cítrico.
ECSENADI202386661A 2021-05-18 2023-11-16 Forma cristalina del compuesto derivado tricíclico, método para preparar la misma y composición farmacéutica que comprende la misma ECSP23086661A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20210064416 2021-05-18

Publications (1)

Publication Number Publication Date
ECSP23086661A true ECSP23086661A (es) 2023-12-29

Family

ID=84140601

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202386661A ECSP23086661A (es) 2021-05-18 2023-11-16 Forma cristalina del compuesto derivado tricíclico, método para preparar la misma y composición farmacéutica que comprende la misma

Country Status (16)

Country Link
US (1) US20240246933A1 (es)
EP (1) EP4342898A4 (es)
JP (2) JP7809725B2 (es)
KR (1) KR102918032B1 (es)
CN (1) CN117321054A (es)
BR (1) BR112023023813A2 (es)
CA (1) CA3219303A1 (es)
CL (1) CL2023003335A1 (es)
CO (1) CO2023015293A2 (es)
EC (1) ECSP23086661A (es)
IL (1) IL308326A (es)
MA (1) MA63141B1 (es)
MX (1) MX2023013624A (es)
PE (1) PE20241190A1 (es)
UA (1) UA130395C2 (es)
WO (1) WO2022245125A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) * 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
KR101827444B1 (ko) * 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
MX375707B (es) * 2015-06-09 2025-03-06 Onconic Therapeutics Inc Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
US9907357B2 (en) 2015-09-24 2018-03-06 Nike, Inc. Fluid-filled chamber for an article of footwear
CN107955001A (zh) * 2016-10-14 2018-04-24 上海汇伦生命科技有限公司 抗肿瘤杂环并咪唑类化合物的药用盐

Also Published As

Publication number Publication date
WO2022245125A1 (ko) 2022-11-24
MX2023013624A (es) 2023-11-30
CN117321054A (zh) 2023-12-29
PE20241190A1 (es) 2024-06-03
KR102918032B1 (ko) 2026-01-27
CA3219303A1 (en) 2022-11-24
EP4342898A1 (en) 2024-03-27
EP4342898A4 (en) 2024-09-11
MA63141B1 (fr) 2026-03-31
IL308326A (en) 2024-01-01
CL2023003335A1 (es) 2024-06-21
BR112023023813A2 (pt) 2024-02-06
UA130395C2 (uk) 2026-02-04
CO2023015293A2 (es) 2023-11-20
US20240246933A1 (en) 2024-07-25
JP7809725B2 (ja) 2026-02-02
JP2025186544A (ja) 2025-12-23
MA63141A1 (fr) 2024-09-30
KR20230157374A (ko) 2023-11-16
JP2024519334A (ja) 2024-05-10

Similar Documents

Publication Publication Date Title
AR121611A2 (es) Inhibidores de glucosilceramida sintasa
AR063710A1 (es) Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden.
ZA202007566B (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
CO2023006515A2 (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma
CL2023001224A1 (es) Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación
AR128717A1 (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2018009500A (es) Sal de maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus metodos de preparacion y usos de la sal de maleato y formas cristalinas.
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso
AR126215A1 (es) Proceso novedoso
AR126196A1 (es) Proceso para preparar inhibidores de egfr
AR124036A1 (es) Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición
AR087346A1 (es) Formulaciones de compuestos de tiofeno
MX2026001703A (es) Preparacion farmaceutica de un derivado de piperazina, metodo de preparacion de la misma y uso de la misma
BR112017012926A2 (pt) precursores de ácido n-acético de alanina, processo de preparação de precursores, uso de precursores, e processo de hidrólise dos precursores
ECSP23086661A (es) Forma cristalina del compuesto derivado tricíclico, método para preparar la misma y composición farmacéutica que comprende la misma
MX2021012544A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.
MX2021000611A (es) Una sal de xinafoato de un compuesto inhibidor de jak.
MX2018012777A (es) Métodos para preparación de ácido obeticólico y derivados de los mismos.
BR112020026507A8 (pt) Composto de isotiazolo[5,4-d]pirimidinas como inibidor de irak4
BR112014003696A2 (pt) sal e polimorfo do composto de pirazolopirimidinona e composição farmacêutica contendo o mesmo método de preparo e seu uso
CO2024009342A2 (es) Sal derivada de triazolona como inhibidor de elastasa de neutrófilos
BR112023024037A2 (pt) Sal farmaceuticamente aceitável de derivado de pirazoloheteroarila, formas cristalinas, composição farmacêutica, usos dos mesmos e métodos para preparar as referidas formas cristalinas e composição farmacêutica
AR131692A1 (es) Formas cristalinas o sales de un compuesto deuterado